Bausch & Lomb Automates Clinical Trial Management with Phase Forward InForm

Global Eye Health Company Signs Multi-Year Agreement to Implement Phase Forward’s EDC Solution

• Press Release
• Source: Phase Forward
• On 9:04 am EDT, Thursday October 29, 2009

WALTHAM, Mass.--(BUSINESS WIRE)--Phase Forward (NASDAQ: PFWD - News), a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year contract with renowned eye health company Bausch & Lomb. The agreement calls for Bausch & Lomb to implement Phase Forward’s InForm™ Global Trial Management (GTM) electronic data capture (EDC) solution, including the Central Coding™ module, in all of its trials, including Surgical, Vision Care and Pharmaceuticals products.

Related Quotes

Symbol	Price	Change
PFWD	15.91	-0.25

{"s" : "pfwd","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Bausch & Lomb will leverage Phase Forward’s InForm GTM to view and act on clinical trial data earlier in the development cycle, and enhance the efficiency and effectiveness with which it manages study procedures and expenditures. The Central Coding module – fully integrated with InForm – will be utilized to streamline the process of coding medical terms for trials, automating manual tasks while increasing coding consistency and accuracy.

“Bausch & Lomb is committed to the use of innovative technology to help develop the highest quality eye health products in the most efficient manner,” said John W. Sheets, Jr., corporate vice president and chief technology officer, Bausch & Lomb. “Clinical trials are a critical element of our product development engine, and Phase Forward’s EDC solution brings a proven solution for automating and optimizing trial management.”

“Bausch & Lomb enjoys a worldwide reputation for high quality eye health products,” said Bob Weiler, chairman and CEO, Phase Forward. “We are proud to be selected by a company of this caliber. Our mission is to become the trusted partner of all of our customers, and we bring this same commitment to this new relationship announced today.”

About Bausch & Lomb

Bausch & Lomb is dedicated to bringing visionary ideas to eye health. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. The Bausch & Lomb name is one of the best-known and most respected healthcare brands in the world. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at www.bausch.com.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Cautionary Statement

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward’s products and services, demand for Phase Forward’s products and services, future business and operations plans of a Phase Forward customer, and the ability of Phase Forward’s customers to realize benefits from the use of Phase Forward’s products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward’s customers to realize benefits from the use of its products and services, the possibility that customers’ needs or plans may change over time, the possibility that the level of demand for Phase Forward’s products and services may vary, regulatory changes and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.

Phase Forward
Elaine Maynard, 781-902-4371
elaine.maynard@phaseforward.com
or
CHEN PR, Inc.
Randy Wambold, 781-672-3119
rwambold@chenpr.com